TABLE 4.
Univariate and Multivariate Analyses of FIB‐4 With Progression to NASH, Cirrhosis, End‐Stage Liver Disease, HCC, and Liver Transplantation
| Unadjusted HR | Progression to NASH | Progression to Cirrhosis | End‐Stage Liver Disease | HCC | Liver Transplantation | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| FIB‐4 | ||||||||||
| <1.3 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| 1.3‐2.66 | 2.13 (1.8 – 2.53) | <0.001 | 1.28 (1.2‐1.46) | <0.001 | 1.21 (1.14‐1.29) | <0.001 | 1.2 (0.9‐1.6) | 0.206 | 1.35 (0.77‐2.37) | 0.291 |
| ≥2.67 | 6.71 (5.49‐8.2) | <0.001 | 2.36 (2.15‐2.58) | <0.001 | 2.11 (1.92‐2.33) | <0.001 | 3.97 (2.96‐5.33) | <0.001 | 10.03 (5.92‐17) | <0.001 |
| aHR* | Progression to NASH | Progression to Cirrhosis | End‐Stage Liver Disease | HCC | Liver Transplantation | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| aHR (95% CI) | P Value | aHR (95% CI) | P Value | aHR (95% CI) | P Value | aHR (95% CI) | P Value | aHR (95% CI) | P Value | |
| FIB‐4 | ||||||||||
| <1.3 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| 1.3‐2.66 | 2.08 (1.75‐2.47) | <0.001 | 1.2 (1.13‐1.28) | <0.001 | 1.14 (1.07‐1.22) | <0.001 | 1.18 (0.89‐1.58) | 0.246 | 1.23 (0.7‐2.16) | 0.482 |
| ≥2.67 | 5.78 (4.72‐7.07) | <0.001 | 2.04 (1.86‐2.24) | <0.001 | 1.86 (1.68‐2.05) | <0.001 | 3.66 (2.71‐4.94) | <0.001 | 7.98 (4.62‐13.79) | <0.001 |
Statistical analyses were performed using Cox regression and results were reported as HR and 95% CI.
*
HR adjusted for risk group (NALFD, NASH, and RISK), sex, race/ethnicity, and clinical characteristics (T2DM, hypertension, MACE, hyperglycemia, high LDL‐C, low HDL‐C, and high triglycerides).